Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy

Clinical and Experimental Allergy

Volumn 44, Issue 3, 2014, Pages 417-428

  Aasbjerg, K ^a   Backer, V ^a   Lund, G ^b   Holm, J ^b   Nielsen, N C ^b   Holse, M ^b   Wagtmann, V R ^b   Wurtzen P A ^b  

^a BISPEBJERG HOSPITAL   (Denmark)

^b ALK ABELLÓ   (Denmark)

Author keywords

Basophil activation; Basophil sensitivity; Blocking factor; Facilitated antigen presentation; IgE; IgG4; Immunotherapy; Nasal challenge; Phlerum pratense; Rhinitis; SCIT; SLIT tablet

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E BLOCKING FACTOR; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG;

ADULT; ALLERGY; ANTIBODY TITER; ANTIGEN PRESENTATION; ARTICLE; BASOPHIL ACTIVATION TEST; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRASS ALLERGY; GRASS POLLEN; HAY FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL PARAMETERS; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHLEUM PRATENSE; PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEASON; SENSITIVITY ANALYSIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL ALLERGEN IMMUNOTHERAPY TABLET; SUBLINGUAL IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; YOUNG ADULT;

ALLERGENS; ANTIBODY SPECIFICITY; ANTIGEN PRESENTATION; ANTIGENS, PLANT; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; NASAL MUCOSA; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SKIN TESTS; TABLETS;

EID: 84894258920     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12241     Document Type: Article

References (50)

1. Hellgren J, Cervin A, Nordling S, Bergman A, Cardell LO. Allergic rhinitis and the common cold-high cost to society. Allergy 2010; 65:776-83.
2. Bousquet J, Schünemann HJ, Zuberbier T et al. Development and implementation of guidelines in allergic rhinitis - an ARIA-GA2LEN paper. Allergy 2010; 65:1212-21.
3. Calderón M, Cardona V, Demoly P. One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions. Allergy 2012; 67:462-76.
4. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-40.
5. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-25.
6. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010; 125:131-8.e1-7
7. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-8.
8. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004; 114:851-7.
9. Marogna M, Tomassetti D, Bernasconi A et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol 2008; 101:206-11.
10. Möller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
11. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009; 123:167-73.e7.
12. Walker SM, Durham SR, Till SJ et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011; 41:1177-200.
13. Calderón MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: the meta-analyses. What have we Learned?. Immunol Allergy Clin North Am 2011; 31:159-73, vii.
14. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011; 41:1235-46.
15. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-71.
16. Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: mechanisms and applications. Clin Dev Immunol 2012; 2012:623474.
17. Shamji MH, Ljørring C, Francis JN et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67:217-26.
18. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012; 129:717-25.e5.
19. Würtzen PA, Lund G, Lund K, Arvidsson M, Rak S, Ipsen H. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy 2008; 38:1290-301.
20. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-5.e2.
21. Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am 2011; 31:191-209, viii.
22. Möbs C, Ipsen H, Mayer L et al. Birch pollen immunotherapy results in long-term loss of Bet v 1-specific T(H)2 responses, transient T(R)1 activation, and synthesis of IgE-blocking antibodies. J Allergy Clin Immunol 2012; 130:1108-16.e6.
23. Lund G, Willumsen N, Holm J, Christensen LH, Würtzen PA, Lund K. Antibody repertoire complexity and effector cell biology determined by assays for IgE-mediated basophil and T-cell activation. J Immunol Methods 2012; 383:4-20.
24. Shamji MH, Wilcock LK, Wachholz PA et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006; 317:71-9.
25. Henmar H, Lund G, Lund L, Petersen A, Würtzen PA. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol 2008; 153:316-23.
26. Nopp A, Johansson SGO, Ankerst J et al. Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation. Allergy 2006; 61:298-302.
27. Scadding GW, Calderon MA, Bellido V et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods 2012; 384:25-32.
28. Leuppi JD, Brannan JD, Anderson SD. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132:151-8.
29. Anderson SD, Brannan J, Spring J et al. A new method for bronchial-provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156:758-65.
30. Pfaar O, Wolf H, Klimek L, Schnitker J, Wüstenberg E. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10, 000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther 2012; 34:2072-81.
31. Dahl R, Kapp A, Colombo G et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-8.e2.
32. Marcucci F, Sensi L, Incorvaia C, Dell'albani I, Di Cara G, Frati F. Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapy. CMA 2012; 10:7.
33. Van Ree R, Van Leeuwen WA, Dieges PH et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy 1997; 27:68-74.
34. Lichtenstein LM, Ishizaka K, Norman PS, Sobotka AK, Hill BM. IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Investig 1973; 52:472-82.
35. Scadding GW, Shamji MH, Jacobson MR et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B. Clin Exp Allergy 2010; 40:598-606.
36. Shamji MH, James LK, Durham SR. Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am 2011; 31:311-23, x.
37. Van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4 + T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1950; 999:163.
38. Gokmen NM, Ersoy R, Gulbahar O et al. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils. Int Arch Allergy Immunol 2012; 159:75-82.
39. Lalek N, Kosnik M, Silar M, Korosec P. Immunoglobulin G-dependent changes in basophil allergen threshold sensitivity during birch pollen immunotherapy. Clin Exp Allergy 2010; 40:1186-93.
40. Nopp A, Cardell LO, Johansson SGO, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. Allergy 2009; 64:811-4.
41. Swamy RS, Reshamwala N, Hunter T et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy. J Allergy Clin Immunol 2012; 130:215-24.e7
42. Van Overtvelt L, Baron-Bodo V, Horiot S et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy 2011; 66:1530-7.
43. Ejrnaes AM, Svenson M, Lund G, Larsen JN, Jacobi H. Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important. Clin Exp Allergy 2006; 36:273-82.
44. Mothes N, Heinzkill M, Drachenberg KJ et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-208.
45. Plewako H, Wosińska K, Arvidsson M et al. Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy. Int Arch Allergy Immunol 2006; 141:346-53.
46. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-9.
47. Larenas-Linnemann D, Cox LS. Immunotherapy and allergy diagnostics committee of the American academy of allergy, asthma and immunology. Ann Allergy Asthma Immunol 2008; 100:137-45.
48. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004; 4:543-8.
49. Aasbjerg K, Torp-Pedersen C, Backer V. Specific immunotherapy can greatly reduce the need for systemic steroids in allergic rhinitis. Allergy 2012; 67:1423-9.
50. Naclerio RM, Adkinson NF, Moylan B et al. Nasal provocation with allergen induces a secondary serum IgE antibody response. J Allergy Clin Immunol 1997; 100:505-10.